BioNTech AG acquires EUFETS AG
"The investment in EUFETS is an excellent fit endowing BioNTech with synergistic platforms and complementary expertise" commented Prof. Dr. Ugur Sahin, CEO of BioNTech AG, and Dr. Klaus Kühlcke, vice president operations of EUFETS, adding, "We are interested to progress EUFETS into a center of excellence that addresses the needs of individualized medicine by developing and providing a wide range of high-quality GMP/GLP services for innovative approaches such as recombinant vaccines, cell based therapies, gene- and immunotherapies.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.